These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
303 related articles for article (PubMed ID: 17996430)
1. Pimecrolimus: skin disposition after topical administration in minipigs in vivo and in human skin in vitro. Gschwind HP; Waldmeier F; Zollinger M; Schweitzer A; Grassberger M Eur J Pharm Sci; 2008 Jan; 33(1):9-19. PubMed ID: 17996430 [TBL] [Abstract][Full Text] [Related]
2. The safety and efficacy of pimecrolimus, 1%, cream for the treatment of Netherton syndrome: results from an exploratory study. Yan AC; Honig PJ; Ming ME; Weber J; Shah KN Arch Dermatol; 2010 Jan; 146(1):57-62. PubMed ID: 20083693 [TBL] [Abstract][Full Text] [Related]
3. Low systemic exposure in infants with atopic dermatitis in a 1-year pharmacokinetic study with pimecrolimus cream 1%*. Lakhanpaul M; Davies T; Allen BR; Schneider D Exp Dermatol; 2006 Feb; 15(2):138-41. PubMed ID: 16433686 [TBL] [Abstract][Full Text] [Related]
4. Low systemic absorption and good tolerability of pimecrolimus, administered as 1% cream (Elidel) in infants with atopic dermatitis--a multicenter, 3-week, open-label study. Staab D; Pariser D; Gottlieb AB; Kaufmann R; Eichenfield LF; Langley RG; Scott G; Ebelin ME; Barilla D; Schmidli H; Burtin P Pediatr Dermatol; 2005; 22(5):465-71. PubMed ID: 16191004 [TBL] [Abstract][Full Text] [Related]
5. Pimecrolimus leads to an apoptosis-induced depletion of T cells but not Langerhans cells in patients with atopic dermatitis. Hoetzenecker W; Ecker R; Kopp T; Stuetz A; Stingl G; Elbe-Bürger A J Allergy Clin Immunol; 2005 Jun; 115(6):1276-83. PubMed ID: 15940147 [TBL] [Abstract][Full Text] [Related]
6. Pimecrolimus: absorption, distribution, metabolism, and excretion in healthy volunteers after a single oral dose and supplementary investigations in vitro. Zollinger M; Waldmeier F; Hartmann S; Zenke G; Zimmerlin AG; Glaenzel U; Baldeck JP; Schweitzer A; Berthier S; Moenius T; Grassberger MA Drug Metab Dispos; 2006 May; 34(5):765-74. PubMed ID: 16467136 [TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 years. Paul C; Cork M; Rossi AB; Papp KA; Barbier N; de Prost Y Pediatrics; 2006 Jan; 117(1):e118-28. PubMed ID: 16361223 [TBL] [Abstract][Full Text] [Related]
8. Review of pimecrolimus cream 1% for the treatment of mild to moderate atopic dermatitis. Hebert AA Clin Ther; 2006 Dec; 28(12):1972-82. PubMed ID: 17296454 [TBL] [Abstract][Full Text] [Related]
9. Binding of pimecrolimus and tacrolimus to skin and plasma proteins: implications for systemic exposure after topical application. Weiss HM; Fresneau M; Moenius T; Stuetz A; Billich A Drug Metab Dispos; 2008 Sep; 36(9):1812-8. PubMed ID: 18524871 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator-blind comparison. Draelos Z; Nayak A; Pariser D; Shupack JL; Chon K; Abrams B; Paul CF J Am Acad Dermatol; 2005 Oct; 53(4):602-9. PubMed ID: 16198779 [TBL] [Abstract][Full Text] [Related]
11. An update on the safety and tolerability of pimecrolimus cream 1%: evidence from clinical trials and post-marketing surveillance. Langley RG; Luger TA; Cork MJ; Schneider D; Paul C Dermatology; 2007; 215 Suppl 1():27-44. PubMed ID: 18174691 [TBL] [Abstract][Full Text] [Related]
12. Clinical management of atopic eczema with pimecrolimus cream 1% (Elidel) in paediatric patients. Eichenfield LF; Thaci D; de Prost Y; Puig L; Paul C Dermatology; 2007; 215 Suppl 1():3-17. PubMed ID: 18174689 [TBL] [Abstract][Full Text] [Related]
13. Treatment with pimecrolimus cream 1% clears irritant dermatitis of the periocular region, face and neck. Mensing CO; Mensing CH; Mensing H Int J Dermatol; 2008 Sep; 47(9):960-4. PubMed ID: 18937664 [TBL] [Abstract][Full Text] [Related]
14. Blood concentrations of pimecrolimus in adult patients with atopic dermatitis following intermittent administration of pimecrolimus cream 1% (Elidel) for up to 1 year. Van Leent EJ; De Vries HJ; Ebelin ME; Burtin P; Scott G; Bos JD J Dermatolog Treat; 2007; 18(1):19-22. PubMed ID: 17365262 [TBL] [Abstract][Full Text] [Related]
15. Pimecrolimus permeates less than tacrolimus through normal, inflamed, or corticosteroid-pretreated skin. Meingassner JG; Aschauer H; Stuetz A; Billich A Exp Dermatol; 2005 Oct; 14(10):752-7. PubMed ID: 16176283 [TBL] [Abstract][Full Text] [Related]
16. The use of topical tacrolimus and pimecrolimus to treat psoriasis: a review. Scheinfeld N Dermatol Online J; 2004 Jul; 10(1):3. PubMed ID: 15347485 [TBL] [Abstract][Full Text] [Related]
17. Discovery of topical calcineurin inhibitors and pharmacological profile of pimecrolimus. Stuetz A; Baumann K; Grassberger M; Wolff K; Meingassner JG Int Arch Allergy Immunol; 2006; 141(3):199-212. PubMed ID: 16926539 [TBL] [Abstract][Full Text] [Related]
18. Inflammatory cell numbers and cytokine expression in atopic dermatitis after topical pimecrolimus treatment. Simon D; Vassina E; Yousefi S; Braathen LR; Simon HU Allergy; 2005 Jul; 60(7):944-51. PubMed ID: 15932386 [TBL] [Abstract][Full Text] [Related]
19. Topical use of pimecrolimus in atopic dermatitis: update on the safety and efficacy. Werfel T J Dtsch Dermatol Ges; 2009 Sep; 7(9):739-42. PubMed ID: 19650820 [TBL] [Abstract][Full Text] [Related]
20. Pimecrolimus cream 1% in the long-term management of adult atopic dermatitis: prevention of flare progression. A randomized controlled trial. Gollnick H; Kaufmann R; Stough D; Heikkila H; Andriano K; Grinienko A; Jimenez P; Br J Dermatol; 2008 May; 158(5):1083-93. PubMed ID: 18341665 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]